Financial Statements — DRUG
Balance Sheet
(in millions CAD)| Metric | FY
2024 | FY
2023 | FY
2022 | FY
2021 |
|---|
| Cash & Equivalents | 5.72 | 6.75 | 11.63 | 19.76 |
| Total Current Assets | 5.99 | 6.81 | 11.95 | 20.04 |
| Total Non-current Assets* | 0.12 | 0.07 | 0.14 | 0.00 |
| Total Assets | 6.10 | 6.88 | 12.09 | 20.04 |
| Total Current Liabilities | 0.53 | 0.28 | 1.47 | -- |
| Total Non-current Liabilities* | 0.04 | 0.00 | 0.07 | -- |
| Total Liabilities | 0.57 | 0.28 | 1.54 | 0.64 |
| Retained Earnings | (34.35) | (31.55) | (24.17) | (9.21) |
| Total Stockholder Equity | 5.54 | 6.60 | 10.54 | 19.40 |
* Derived from reported values
Income Statement
(in millions CAD) (except per-share rows)| Metric | FY
2024 | FY
2023 | FY
2022 | FY
2021 |
|---|
| Research & Development | 1.18 | 5.00 | 12.18 | 6.31 |
| Selling, General & Admin | 0.26 | 0.28 | 0.48 | 0.20 |
| Pretax Income* | (2.80) | (7.37) | (14.96) | (8.65) |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | (2.80) | (7.37) | (14.96) | (8.65) |
| Basic EPS | (0.65) | (1.98) | -- | -- |
| Diluted EPS | (0.65) | (1.98) | (1.21) | -- |
* Derived from reported values
Cash Flow Statement
(in millions CAD)| Metric | FY
2024 | FY
2023 | FY
2022 | FY
2021 |
|---|
| Operating Cash Flow | (1.85) | (7.02) | (13.59) | (7.32) |
| Financing Cash Flow | 0.81 | 2.19 | 5.20 | 26.06 |
